SEC 13F Intelligence

Managers / Q1 2019 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$1.6B
Q1 2019
Positions
26
Filings on Record
15
2019–present window
Filed
May 15, 2019
original filing

Summary

Consonance Capital Management LP reported $1.6B in U.S.-listed holdings across 26 positions for Q1 2019.

Its largest position, Amarin, represents 14.4% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+73.0%
share of reported value
Largest Position
+14.4%
Amarin

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 82.3%Other: 17.2%US DOMESTIC: 0.5%
  • Common Stock · 82.3% · $1.3B
  • Other · 17.2% · $273M
  • US DOMESTIC · 0.5% · $8M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
AMARIN CORP PLCNEW+10.99M10.99M+$228M$228M
UTHRUNITED THERAPEUTICS CORP DELNEW+1.23M1.23M+$144M$144M
PCRXPACIRA PHARMACEUTICALS INCNEW+3.65M3.65M+$139M$139M
QUREUNIQURE NVNEW+1.99M1.99M+$118M$118M
MYGNMYRIAD GENETICS INCNEW+3.31M3.31M+$110M$110M
RETROPHIN INCNEW+4.03M4.03M+$91M$91M
CN2CATALYST PHARMACEUTICALS INCNEW+17.88M17.88M+$91M$91M
AERIE PHARMACEUTICALS INCNEW+1.70M1.70M+$81M$81M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2019

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AMARIN CORP PLCSPONS ADR NEW14.40%$228M10.99M
2UTHRUNITED THERAPEUTICS CORP DELhistory →COM9.08%$144M1.23M
3PCRXPACIRA PHARMACEUTICALS INChistory →COM8.77%$139M3.65M
4QUREUNIQURE NVhistory →SHS7.48%$118M1.99M
5MYGNMYRIAD GENETICS INChistory →COM6.94%$110M3.31M
6RETROPHIN INCCOM5.76%$91M4.03M
7CN2CATALYST PHARMACEUTICALS INChistory →COM5.75%$91M17.88M
8AERIE PHARMACEUTICALS INCCOM5.09%$81M1.70M
9VNDAVANDA PHARMACEUTICALS INChistory →COM4.95%$78M4.26M
10VCELVERICEL CORPhistory →COM4.74%$75M4.29M
11URGNUROGEN PHARMA LTDhistory →COM4.10%$65M1.76M
12OXFORD IMMUNOTEC GLOBAL PLCORD SHS2.84%$45M2.61M
13CORTCORCEPT THERAPEUTICS INChistory →COM2.78%$44M3.75M
14EPIZYME INCCOM2.72%$43M3.48M
15OMEROMEROS CORPhistory →COM2.33%$37M2.12M
16KDMNKADMON HLDGS INChistory →COM1.94%$31M11.63M
17KARYOPHARM THERAPEUTICS INCCOM1.90%$30M5.16M
18AUPHAURINIA PHARMACEUTICALS INChistory →COM1.73%$27M4.22M
19CHEMOCENTRYX INCCOM1.46%$23M1.67M
20SVRASAVARA INChistory →COM1.44%$23M3.09M
21ADMAADMA BIOLOGICS INChistory →COM1.10%$17M4.59M
22AKBAAKEBIA THERAPEUTICS INChistory →COM0.74%$12M1.43M
23IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM0.68%$11M1.14M
24ANIPANI PHARMACEUTICALS INChistory →COM0.64%$10M142.9K
25RADIUS HEALTH INCNOTE 3.000% 9/00.47%$8M9.00M
26IMMUIMMUNOMEDICS INCCOM0.18%$3M145.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.